
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Graphene Nano | LSE:GRPH | London | Ordinary Share | GB00B9BBJ076 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.93 | 1.86 | 2.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/10/2017 11:01 | 20% spread LOL! | ![]() telbap | |
09/10/2017 10:53 | Once the debt re-structuring is confirmed....The share price here will Rally significantly, tie that in with some contract details and from this lowly price we should have ourselves a multi-bagger.. | the egregore | |
09/10/2017 10:08 | Unusual tight spread online 1.28-1.305p | ![]() dave4545 | |
09/10/2017 07:27 | Sp looking like its ready to take off in expectation of confirmation of Debt re-structuring completion RNS and Contract news... | the egregore | |
08/10/2017 11:52 | [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance | Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@allianc Read more: A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment | cool druid | |
07/10/2017 17:28 | Rather downbeat assessment of GPRH's prospects. | ![]() obbig60 | |
07/10/2017 14:18 | #GRPH HEADLINE FT RECOVERY STOCK Small-cap focus: # Graphene Nanochem😉 | dice1950 | |
06/10/2017 20:33 | Leedskier seems quiet these days? It appears this dog of a company is still going one direction and the only losers are the PI’s. Wonder what patents they have registered and in who’s name? | ![]() roddyb | |
03/10/2017 21:32 | Blatent attemps by MMs trying hard to suck in PIs with crazy hikes in the price only to keep the spread at 40%! | ![]() telbap | |
02/10/2017 16:27 | And down we go..... | ![]() telbap | |
30/9/2017 07:48 | Blue7 That has been on their website for at least two years, all part of the deceit and or incompetence . . . . . Not many straws left to grab, if any . . . . . | 1sillydoris | |
29/9/2017 10:51 | Sold out after results. Managed to get some 1.08p last week so managed to make a few quid out of them. | ![]() dave4545 | |
29/9/2017 06:44 | Only hot if the first half year figures get released today. | mdvorkin | |
29/9/2017 06:34 | Interesting strategy Egregore. Good luck.... | ![]() bernieboy | |
28/9/2017 20:29 | Blueshoes>>> My criteria is simple and these fit. (1) Limited Shares in issue (Tick just 200 mill) (2) Priced to go Bust (Tick)(3) Company has at the bare minimum something to sell (tick)(4) Majority of shares i.e. 60% or more held by 1 or more major holders (tick) (5) Assured that on the sniff of positive news the Swarm will hit these like locust looking to buy in (Tick). Far as I'm concerned these are currently Very Hot Property..yet few realise it..We will now wait and see...I will continue to suck a few more up sub 1.6p.. | the egregore | |
28/9/2017 12:47 | Well Done... Volume will pick up this afternoon.... | blueshoes7 | |
28/9/2017 12:41 | Just bought another two tranches 150k and 167 k.. Will continue to accumulate.. | the egregore |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions